首页   氯氮平(非典型抗精神病药)诱发胃肠动力不足:可能危及生命的不良事件(文献综述)

氯氮平(非典型抗精神病药)诱发胃肠动力不足:可能危及生命的不良事件(文献综述)

时间:2019-07-03


Clozapine induced gastrointestinal hypomotility: A potentially life threatening adverse event.

氯氮平(非典型抗精神病药)诱发胃肠动力不足:可能危及生命的不良事件(文献综述)


Abstract

OBJECTIVE:

The haematological and cardiac complications of clozapine have been well documented. Recent evidence from pharmacovigilance databases suggests that gastrointestinal (GI) complications are the leading cause of clozapine related deaths. This review aims to describe clinical features along with preventative and treatment options.

目的:目前已充分记录了氯氮平引起的血液并发症和心脏并发症。来自药物警戒数据库的最新证据表明,胃肠道(GI)并发症是与氯氮平相关死亡的主要原因。本综述旨在描述临床特征以及预防和治疗方案。

METHOD:

A review of MEDLINE via PubMed searching for all articles published up to February of 2016. Inclusion criteria were articles that provided clinical or epidemiological information relating to the diagnosis, outcome, management or pathophysiology of clozapine related gastrointestinal disorders in humans.

方法:通过PubMed检索MEDLINE,检索截至20162月发表的所有文章。纳入标准是提供与人氯氮平相关胃肠道疾病的诊断、结果、管理或病理生理学相关的临床或流行病学信息的文章。

RESULTS:

Three large case series were identified with 104 cases, 20 of these reported clinical details. A further 52 cases reports were included. Median age was 40, with 79% being male, mean daily clozapine dose was 453 mg. Mortality was 38% withsurvivors being younger (39 vs. 42), on lower daily doses (400 mg vs. 532 mg), more likely to be female (32% vs. 6%). Four patients were re-challenged with clozapine following CIGH, two suffered a recurrence.

结果:纳入了三个大型病例系列,含有104例,其中20例报告了临床细节。同时包括52个远期观察案例报告。中位年龄为40岁,其中79%为男性,平均每日氯氮平剂量为453mg。幸存者年龄较小(3942),死亡率为38%,每日剂量较低(400mg532mg),更可能是女性(32%:6%)。 4名患者在CIGH后再次接受氯氮平治疗,其中2名患者复发。

CONCLUSION:

Risk factors for CIGH appear to be older age, male gender, patients in the first four months of treatment, co-prescription of constipating agents, higher daily dose of clozapine, and previous CIGH. Risk factors for death were older age and male gender. Patients receiving clozapine should be counselled about the dangers of constipation and to report new GI symptoms. Once severe CIGH has occurred clozapine should be halted and reviewed with bowel symptoms managed promptly. Re-challenging with clozapine may present substantial risks due to the severity of CIGH and a paucity of evidence. From the available evidence a treatment strategy has been proposed. Further prospective data regarding CIGH are needed to allow a better assessment of the scale of the problem with the development and testing of treatment strategies.

结论:CIGH(题目缩写)的危险因素似乎是更大年龄、男性、处于接受治疗前四个月的患者,便秘药物的共同处方,氯氮平的日剂量较高以及之前患CIGH史。死亡的风险因素是年龄较大和男性。接受氯氮平治疗的患者应该咨询便秘的危险并报告新的胃肠道症状。一旦发生严重的CIGH,应立即停用氯氮平,并及时治疗肠道症状。由于CIGH的严重性和缺乏证据,再次应用氯氮平可能会带来很大的风险。根据现有证据,提出了治疗策略。目前需要有关CIGH的更多前瞻性数据,以便通过开发和测试治疗策略来更好进行临床评估。

绘佳医疗www.zhonghuijia.cn

专注于为大病患者减轻治疗花销

打造全民健康管理体系



热门评论

绘佳医疗是全球寻药和跨境医疗服务的领导者,是爱心筹旗下医疗服务品牌,成立5年以来,已累计为60万大病患者提供了大病筹款、出国看病、药房对接、病历翻译、远程咨询等服务,致力于帮助大病家庭改善医疗资金的支付能力和帮助患者降低治疗花销。

免责声明:本文所表达的任何关于疾病的建议都不应该被视为医生的建议或替代品,请咨询您的治疗医生了解更多细节。本站信息仅供参考,绘佳医生不承担任何责任。

相关文章推荐:

走进绘佳

我们为您提供专业的医药信息服务

赴印老挝看病方案

一站式赴印老挝看病方案,保姆式贴心服务。医生根据患者的身体状况,指导患者服药。医院药房直接拿药,确保药品疗效及药品价格透明。

远程咨询

足不出户,借助远程通讯设备与国外权威医学专家面对面咨询预约,提供健康建议。

出国看病

帮助国内患者到美国、印度等医学发达国家的权威医院,接受全球最好的治疗。

一流医院官方合作

顶级国外医院正式授权合作

国外就医绿色通道

绿色就医通道,免排队,直达知名专家,提供个性化治疗方案

管家式海外服务

在当地设立办事处,与当地人合作,为用户提供安全放心的一站式服务

绘佳医疗品牌担保

爱心筹唯一指定海外健康咨询服务机构,为百万病友家庭提供安全可靠、规范可行的解决方案。

重症专家全程指导

专家团队提供专业1对1咨询,海外肿瘤专家提供诊疗及归国后随诊服务

回国后健康跟踪

国外治疗完毕后,提供与国外专家的直接沟通渠道,随时咨询患者的各类问题,无需漫长等待

联系我们

电话咨询

0532-80921197

周一至周日 9:00-22:00
公司地址

青岛市龙城路31号卓越世纪中心1号楼24层

扫码加健康顾问微信咨询

在线咨询

咨询热线

0532-80921197

健康顾问验证
爱心筹

爱心筹旗下医疗品牌
帮助患者降低花销

氯氮平(非典型抗精神病药)诱发胃肠动力不足:可能危及生命的不良事件(文献综述)

发布时间:2019-07-03




立即咨询

Clozapine induced gastrointestinal hypomotility: A potentially life threatening adverse event.

氯氮平(非典型抗精神病药)诱发胃肠动力不足:可能危及生命的不良事件(文献综述)


Abstract

OBJECTIVE:

The haematological and cardiac complications of clozapine have been well documented. Recent evidence from pharmacovigilance databases suggests that gastrointestinal (GI) complications are the leading cause of clozapine related deaths. This review aims to describe clinical features along with preventative and treatment options.

目的:目前已充分记录了氯氮平引起的血液并发症和心脏并发症。来自药物警戒数据库的最新证据表明,胃肠道(GI)并发症是与氯氮平相关死亡的主要原因。本综述旨在描述临床特征以及预防和治疗方案。

METHOD:

A review of MEDLINE via PubMed searching for all articles published up to February of 2016. Inclusion criteria were articles that provided clinical or epidemiological information relating to the diagnosis, outcome, management or pathophysiology of clozapine related gastrointestinal disorders in humans.

方法:通过PubMed检索MEDLINE,检索截至20162月发表的所有文章。纳入标准是提供与人氯氮平相关胃肠道疾病的诊断、结果、管理或病理生理学相关的临床或流行病学信息的文章。

RESULTS:

Three large case series were identified with 104 cases, 20 of these reported clinical details. A further 52 cases reports were included. Median age was 40, with 79% being male, mean daily clozapine dose was 453 mg. Mortality was 38% withsurvivors being younger (39 vs. 42), on lower daily doses (400 mg vs. 532 mg), more likely to be female (32% vs. 6%). Four patients were re-challenged with clozapine following CIGH, two suffered a recurrence.

结果:纳入了三个大型病例系列,含有104例,其中20例报告了临床细节。同时包括52个远期观察案例报告。中位年龄为40岁,其中79%为男性,平均每日氯氮平剂量为453mg。幸存者年龄较小(3942),死亡率为38%,每日剂量较低(400mg532mg),更可能是女性(32%:6%)。 4名患者在CIGH后再次接受氯氮平治疗,其中2名患者复发。

CONCLUSION:

Risk factors for CIGH appear to be older age, male gender, patients in the first four months of treatment, co-prescription of constipating agents, higher daily dose of clozapine, and previous CIGH. Risk factors for death were older age and male gender. Patients receiving clozapine should be counselled about the dangers of constipation and to report new GI symptoms. Once severe CIGH has occurred clozapine should be halted and reviewed with bowel symptoms managed promptly. Re-challenging with clozapine may present substantial risks due to the severity of CIGH and a paucity of evidence. From the available evidence a treatment strategy has been proposed. Further prospective data regarding CIGH are needed to allow a better assessment of the scale of the problem with the development and testing of treatment strategies.

结论:CIGH(题目缩写)的危险因素似乎是更大年龄、男性、处于接受治疗前四个月的患者,便秘药物的共同处方,氯氮平的日剂量较高以及之前患CIGH史。死亡的风险因素是年龄较大和男性。接受氯氮平治疗的患者应该咨询便秘的危险并报告新的胃肠道症状。一旦发生严重的CIGH,应立即停用氯氮平,并及时治疗肠道症状。由于CIGH的严重性和缺乏证据,再次应用氯氮平可能会带来很大的风险。根据现有证据,提出了治疗策略。目前需要有关CIGH的更多前瞻性数据,以便通过开发和测试治疗策略来更好进行临床评估。

绘佳医疗www.zhonghuijia.cn

专注于为大病患者减轻治疗花销

打造全民健康管理体系



绘佳医疗是全球寻药和跨境医疗服务的领导者,是爱心筹旗下医疗服务品牌,成立5年以来,已累计为60万大病患者提供了大病筹款、出国看病、药房对接、病历翻译、远程咨询等服务,致力于帮助大病家庭改善医疗资金的支付能力和帮助患者降低治疗花销。






立即咨询
免责声明:本文所表达的任何关于疾病的建议都不应该被视为医生的建议或替代品,请咨询您的治疗医生了解更多细节。本站信息仅供参考,绘佳医生不承担任何责任。
上一篇 下一篇

相关文章推荐:

主营业务

赴印老挝看病方案

一站式赴印老挝看病方案,保姆式贴心服务。医生根据患者的身体状况,指导患者服药。医院药房直接拿药,确保药品疗效及药品价格透明。

远程咨询

足不出户,借助远程通讯设备与国外权威医学专家面对面咨询预约,提供健康建议。

出国看病

帮助国内患者到美国、印度等医学发达国家的权威医院,接受全球最好的治疗。

办公环境

品牌实力

一流医院官方合作

顶级国外医院正式授权合作

国外就医绿色通道

绿色就医通道,免排队,直达知名专家,提供个性化治疗方案

管家式海外服务

在当地设立办事处,与当地人合作,为用户提供安全放心的一站式服务

绘佳医疗品牌担保

爱心筹唯一指定海外健康咨询服务机构,为百万病友家庭提供安全可靠、规范可行的解决方案。

重症专家全程指导

专家团队提供专业1对1咨询,海外肿瘤专家提供诊疗及归国后随诊服务

回国后健康跟踪

国外治疗完毕后,提供与国外专家的直接沟通渠道,随时咨询患者的各类问题,无需漫长等待

药物百科: